Supreme™-NSCLC is the first-of-its-kind, cloud-native AI-powered clinical decision support (CDS) system purpose-built for non-small cell lung cancer (NSCLC). Designed to fit seamlessly into clinical workflows, Supreme™ leverages a multi-modal AI engine that integrates both DNA and RNA data—alongside previously discarded or “noisy” genomic signals—to generate real-time, evidence-based treatment recommendations tailored to each patient’s tumor biology.
Unlike static platforms limited to DNA variant matching, Supreme™ dynamically interprets the molecular complexity of NSCLC through proprietary AI modules: MESiCA (mutational signatures), STAMP (RNA-based predictive modeling), and TVA (tumor variant analysis). This layered approach enables the identification of likely responders, resistance markers, and combination therapy opportunities—supporting oncologists at the point of care with highly actionable insights.
Supreme™-NSCLC is FDA-exempt under CDS guidelines, allowing for rapid iteration and continuous performance improvement. Deployed as a plug-and-play SaaS on Google Cloud (with on-premise options), it ensures effortless EHR and DSS integration across hospital systems and tumor boards.
Built on 7+ years of research and clinically validated by leading cancer centers, Supreme™ is already in use within multidisciplinary tumor boards to improve clinical confidence in treatment selection and streamline decision-making. It supports oncologists without replacing their judgment—offering full transparency into the biological rationale behind each recommendation.
Whether for standard of care alignment, off-label strategies, or identifying patients for clinical trials, Supreme™-NSCLC empowers oncology teams to move faster, smarter, and with more precision—unlocking deeper value from existing genomic data.
